Groundbreaking Cancer Therapy Research: DMSO and Natural Dyes

Mike Adams from Brighteon Broadcast News and Natural News has brought to light research on an alternative cancer therapy involving dimethyl sulfoxide (DMSO) and natural dyes such as hematoxylin and phycocyanin. Historical studies, including those from Japan and the work of Dr. Eli Jordan Tucker Jr., indicate that this combination targets tumors with minimal side effects. Despite its potential, these findings were largely suppressed by the FDA and the American Cancer Society (ACS).

Research Highlights

Phycocyanin, a blue pigment from spirulina, was found in Japanese studies to induce apoptosis, or programmed cell death, in cancer cells without affecting healthy tissues. Hematoxylin, derived from logwood, showed strong tumor-killing properties when used with DMSO. DMSO is a solvent that penetrates tissues, enabling it to deliver therapeutic compounds directly to malignant cells.

FDA’s Stance on Alternative Therapies

Dr. Tucker's work in the 1960s demonstrated success in treating terminal cancer patients with DMSO-hematoxylin infusions, including fibrosarcoma and non-Hodgkin’s lymphoma cases. However, the FDA halted DMSO research in 1965, and the ACS dismissed the therapy as unproven in 1971, potentially suppressing discoveries that could impact the chemotherapy industry.

Adams claims this suppression was intentional, aimed at safeguarding the profits of the chemotherapy sector. Despite Dr. Tucker’s dismissal and the blacklisting of his research, international studies continued to affirm the therapy’s effectiveness, particularly for cervical, breast, and prostate cancers, with no relapse reported.

Modern Developments

Currently, some independent researchers are exploring these protocols. Topical treatments using DMSO-hematoxylin mixtures hold promise for surface tumors like skin or breast cancers. IV administration could be beneficial for deeper malignancies. Phycocyanin from spirulina is being investigated for its anti-angiogenic properties, which inhibit the growth of new blood vessels to tumors.

Challenges include limited access to pure compounds and the need for clinical validation. Adams cautions against self-experimentation but advocates for further research, emphasizing that this is knowledge the cancer industry might prefer to remain undiscovered.

Conclusion

As the interest in non-toxic cancer therapies rises, DMSO and natural dyes offer a potential paradigm shift that challenges Big Pharma’s dominance. While mainstream acknowledgment may be lacking, the research continues among independent scientists and remains documented in archives of suppressed medical studies.